Research programme: melanotransferrin conjugated therapeutics - biOasis/MedImmune

Drug Profile

Research programme: melanotransferrin conjugated therapeutics - biOasis/MedImmune

Latest Information Update: 09 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Developer biOasis Technologies; MedImmune
  • Class Drug conjugates
  • Mechanism of Action Biological transport stimulants; Transferrin-binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuropathic pain

Most Recent Events

  • 12 May 2015 Preclinical trials in Neuropathic pain in Canada (Parenteral)
  • 12 May 2015 Preclinical pharmacodynamics and pharmacokinetics data in Neuropathic pain released by biOasis Technologies
  • 17 Mar 2014 MedImmune and biOasis enters into a license agreement for second generation versions of biOasis' Transcend™ technology platform
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top